PLUR Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	6 843.00
Average Volume	26 838.00
Market Cap	27.78M
EPS	$0 ( 2024-04-26 )
Next earnings date	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.150
ATR14	$0.0640 (1.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-23	Franco-yehuda Chen	Buy	355 000	Common Stock
2024-01-23	Aberman Zami	Buy	44 100	Common Stock
2024-01-23	Birger Pinhas Doron	Buy	39 900	Common Stock
2024-01-23	Shemesh-rasmussen Maital	Buy	38 150	Common Stock
2024-01-23	Yanay Yaky	Buy	700 000	Common Stock

INSIDER POWER
99.91
Last 95 transactions
Buy: 8 548 074 \| Sell: 1 004 814

Pluri Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pluri Inc. Financials

Annual	2023
Revenue:	$287 000
Gross Profit:	$278 000 (96.86 %)
EPS:	$-0.770

FY	2023
Revenue:	$287 000
Gross Profit:	$278 000 (96.86 %)
EPS:	$-0.770

FY	2022
Revenue:	$234 000
Gross Profit:	$-41.36M (-17 674.79 %)
EPS:	$-1.270

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.770

Financial Reports:

No articles found.

Pluri Inc.

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.